首页> 美国卫生研究院文献>Mediators of Inflammation >Dunye Guanxinning Improves Acute Myocardial Ischemia-Reperfusion Injury by Inhibiting Neutrophil Infiltration and Caspase-1 Activity
【2h】

Dunye Guanxinning Improves Acute Myocardial Ischemia-Reperfusion Injury by Inhibiting Neutrophil Infiltration and Caspase-1 Activity

机译:敦煌冠心宁通过抑制中性粒细胞浸润和Caspase-1活性改善急性心肌缺血-再灌注损伤

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Acute myocardial infarction is the most serious manifestation of cardiovascular disease, and it is a life-threatening condition. Dunye Guanxinning (DG) is a protective traditional Chinese patent herbal medicine with high clinical efficacy and suitable for the treatment of myocardial infarction. However, the mechanism through which it is beneficial is unclear. In this study, we hypothesized that DG improves acute myocardial ischemia-reperfusion injury by inhibiting neutrophil infiltration and caspase-1 activity. We found that DG administration decreased infarct size and cardiomyocyte apoptosis and improved left ventricular ejection fraction, fractional shortening, end-systolic volume index, end-systolic diameter, and carotid arterial blood flow output in rats. DG administration also improved hemorheological parameters, myocardial damage biomarkers, and oxidative stress indexes. The findings showed that DG administration inhibited neutrophil infiltration and reduced the serum interleukin-1 beta (IL-1β) level and myocardial IL-1β maturation. Moreover, DG administration inhibited caspase-1 activity and activated adenosine monophosphate-activated protein kinase (AMPK) phosphorylation in rat hearts. These results suggested that DG administration inhibits inflammasome activity and IL-1β release through the AMPK pathway. Our findings support the clinical efficacy of DG and partially reveal its mechanism, which is beneficial for understanding the therapeutic effects of this protective traditional Chinese patent drug.
机译:急性心肌梗塞是心血管疾病最严重的表现,是威胁生命的疾病。盾业冠心宁(DG)是一种保护性中成药,具有较高的临床疗效,适用于心肌梗塞的治疗。但是,尚不清楚其有益机制。在这项研究中,我们假设DG通过抑制中性粒细胞浸润和caspase-1活性来改善急性心肌缺血-再灌注损伤。我们发现DG给药可减少大鼠的梗塞面积和心肌细胞凋亡,并改善左心室射血分数,缩短分数,收缩末期容积指数,收缩末期直径和颈动脉血流量。 DG的给药还改善了血液流变学参数,心肌损伤生物标志物和氧化应激指数。研究结果表明,DG给药可抑制中性粒细胞浸润,并降低血清白介素1β(IL-1β)水平和心肌IL-1β成熟。此外,DG给药可抑制大鼠心脏中的caspase-1活性并激活腺苷单磷酸激活的蛋白激酶(AMPK)磷酸化。这些结果表明,DG的施用抑制了炎性体活性并且通过AMPK途径释放了IL-1β。我们的研究结果支持了DG的临床疗效,并部分揭示了DG的机制,这有助于了解这种保护性中成药的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号